Nuvectis Pharma, Inc. - Common Stock (NVCT)
6.7900
-0.4500 (-6.22%)
Nuvectis Pharma, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment
The company specializes in creating targeted, small-molecule drugs that are designed to improve the outcomes of patients suffering from specific types of tumors. By leveraging cutting-edge research and technology, Nuvectis aims to advance its drug candidates through clinical trials, ultimately striving to bring effective therapeutic options to the market for various forms of cancer. The company's commitment to addressing unmet medical needs positions it as a significant player in the field of oncology.
Previous Close | 7.240 |
---|---|
Open | 7.250 |
Bid | 6.790 |
Ask | 6.900 |
Day's Range | 6.585 - 7.400 |
52 Week Range | 4.440 - 12.10 |
Volume | 131,806 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 112,548 |
News & Press Releases
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter’s option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · February 7, 2025
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · February 4, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 3, 2025
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · December 10, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/14/NVCT.png?width=1200&height=800&fit=crop)
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.
Via Benzinga · November 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/14/Oil-Price-Photo-by-William-Potter-on-Shu.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 14, 2024
![](https://www.abnewswire.com/uploads/1731535833.png)
Nuvectis Pharma (NASDAQNVCT) has shared promising interim data from its Phase 1b study of NXP800, a drug candidate for treating platinum-resistant, ARID1a-mutated ovarian cancer. This patient population faces limited treatment options, and any indication of tumor stability or reduction is significant. The latest results reveal that NXP800, as a single-agent therapy, has led to stable disease in six patients and an unconfirmed partial response in one patient, which includes some cases of tumor shrinkage. These findings indicate that NXP800's effect even at a reduced dose, pointing to its potential as a potential therapeutic option in this challenging cancer subtype.
Via AB Newswire · November 14, 2024
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
By Nuvectis Pharma, Inc. · Via GlobeNewswire · November 14, 2024
![](https://public.newsdirect.com/686948318/eNzfLijJ.png)
The report covers Nuvectis (NASDAQNVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).
Via News Direct · October 28, 2024
![](https://mms.businesswire.com/media/20241028976787/en/2285595/5/LOGO_%281%29.jpg)
Nuvectis Pharma (NASDAQNVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial targeting platinum resistant, ARID1a-mutated ovarian cancer, with a data update expected soon. This pipeline of innovative candidates has positioned Nuvectis at the forefront of precision oncology, and the market appears to be starting to take more notice as the company approaches important clinical milestones. Please refer to the disclaimers and disclosures also linked at the end of the report which it is subject to. Nothing contained herein is intended to serve as financial or investment advice.
By PESG Research · Via Business Wire · October 28, 2024
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain).
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 23, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 16, 2024
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 7, 2024
![](https://public.newsdirect.com/673585564/g6U9qE2m.png)
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQNVCT), Silexion NASDAQ:SLXNNASDAQSLXN)
Via News Direct · September 19, 2024
![](https://public.newsdirect.com/845770131/mJlrHoNm.png)
Report spotlights Nuvectis Pharma's (NASDAQNVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data
Via News Direct · September 16, 2024
![](https://mms.businesswire.com/media/20240915045508/en/2243230/5/logo.jpg)
Summit Therapeutics’ Breakthrough with Ivonescimab
By PESG Research · Via Business Wire · September 16, 2024
![](https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png)
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 5, 2024
![](https://public.newsdirect.com/693388467/kYWD48IG.png)
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
Via News Direct · August 29, 2024
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
Nuvectis Pharma (NASDAQNVCT) continues to affirm its position as a trailblazer in precision oncology, as highlighted in their Q2 2024 financial results and business updates. The company's steadfast commitment to developing targeted therapies for unmet medical needs, coupled with prudent financial management, paints a promising picture for the months ahead.
Via AB Newswire · August 15, 2024
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
A recently published market report showcases how the precision medicine market in the United States is on the brink of a remarkable expansion, with projections estimating its size to surge from USD 24.95 billion in 2023 to an astounding USD 76.12 billion by 2033. This astounding growth trajectory, with a CAGR of 11.80%, highlights the unique potential of precision medicine in disrupting healthcare. Amidst this changing landscape, Nuvectis Pharma (NASDAQNVCT) stands out as a unique and innovative player that may capitalize on the burgeoning market opportunities.
Via AB Newswire · July 18, 2024
Precision Medicine M&A is Transforming the Future of the Biotech Industry
In the ever-evolving landscape of biotechnology, mergers and acquisitions (M&A) are emerging as pivotal mechanisms driving strategic realignments and innovative endeavors. A closer examination of these trends not only unveils the dynamic nature of the industry but also sheds light on the transformative potential of precision medicine. This article delves deep into the evolving paradigm of biotech M&A, with a focused lens on the burgeoning field of precision medicine and its profound implications for industry growth.
Via AB Newswire · June 17, 2024
![](https://investorplace.com/wp-content/uploads/2021/08/penny-stocks-1600.jpg)
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
Via InvestorPlace · May 28, 2024